Discovery Faces Another Surfaxin Setback

Drug Industry Daily
A A
The FDA has sent Discovery Laboratories a third approvable letter for Surfaxin, a treatment for the prevention of respiratory distress syndrome in premature infants.

To View This Article:

Login

Subscribe To Drug Industry Daily